NCT00482378 is a Phase 1, PHASE2 clinical trial of Pamidronate in Multiple Myeloma and Plasma Cell Neoplasm, sponsored by Mayo Clinic.

Who is sponsoring NCT00482378?

NCT00482378 is sponsored by Mayo Clinic.

What drugs are being tested in NCT00482378?

Interventions in NCT00482378: Pamidronate, Zoledronic acid, Sm 153 lexidronam.

What condition does NCT00482378 study?

NCT00482378 studies Multiple Myeloma and Plasma Cell Neoplasm, Pain.

Is NCT00482378 still recruiting?

NCT00482378 is currently completed. Last updated 14 August 2018.

Last reviewed 2018-08-14 · How we verify

NCT00482378

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid or Pamidronate in Treating Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain

Completed Phase 1, PHASE2 Last updated 14 August 2018

What this trial tests

Phase 1, PHASE2 trial testing Pamidronate in Multiple Myeloma and Plasma Cell Neoplasm in 39 participants. Completed in 2 December 2008.

Timeline

21 March 2005

Primary endpoint
22 May 2007

2 December 2008

Quick facts

Lead sponsor	Mayo Clinic
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	39
Start date	21 March 2005
Primary completion	22 May 2007
Estimated completion	2 December 2008
Sites	1 location across United States

Drugs / interventions tested

Pamidronate — full drug profile →
Zoledronic acid (ZOLEDRONIC ACID) — full drug profile →
Sm 153 lexidronam

Conditions studied

Multiple Myeloma and Plasma Cell Neoplasm — all drugs for Multiple Myeloma and Plasma Cell Neoplasm →
Pain — all drugs for Pain →

Sponsor

Mayo Clinic

Who can join

Adults 18 to 120, any sex, with Multiple Myeloma and Plasma Cell Neoplasm or Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Radioactive drugs, such as samarium Sm 153 lexidronam pentasodium, may carry radiation directly to cancer cells and not harm normal cells. Zoledronic acid and pamidronate may help relieve bone pain caused by multiple myeloma. Giving samarium Sm 153 lexidronam pentasodium together with zoledronic acid or pamidronate may be an effective treatment for multiple myeloma. PURPOSE: This phase I/II trial is studying the side effects and best dose of samarium Sm 153 lexidronam pentasodium when given together with zoledronic acid or pamidronate and to see how well it works in treating patients with relapsed or refractory multiple myeloma and bone pain.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Beyond Palliation: Therapeutic Applications of <sup>153</sup>Samarium-EDTMP.
Wilky BA, Loeb DM. · · 2013 · cited 6× · PMID 25664221 · DOI 10.4172/2161-1459.1000131

Verify or expand the search:

Other trials of Pamidronate

Trials testing the same drug.

NCT00128297 — Pamidronate Administration in Breast Cancer Patients With Bone Metastases · Phase 4 · completed

Other recruiting trials for Multiple Myeloma and Plasma Cell Neoplasm

Currently open trials in the same condition.

NCT00544115 — Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders · Phase 2 · active not recruiting

Other Mayo Clinic trials

Trials by the same sponsor.

NCT07126548 — A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men · NA · not yet recruiting
NCT07221656 — Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration · not yet recruiting
NCT06891001 — The Utilization of a Shoe Insert on Individuals With Unilateral Greater Trochanteric Pain Syndrome on Single Leg Stance, · NA · not yet recruiting
NCT07169799 — Impact of Cryotherapy Spray (Tru-Freeze) for the Eradication of Gastric Antral Vascular Ectasia (ICE-GAVE) · NA · recruiting
NCT07086183 — Perioperative Risk in Patients on Chronic Aspirin Undergoing Craniotomy · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00482378 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mayo Clinic
Last refreshed: 14 August 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00482378.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing